We're honored to support RapidPulse, Inc. as they receive?FDA approval for an Investigational Device Exemption study of their groundbreaking cyclic aspiration system. This new approach is aimed at improving treatment efficacy for patients with acute ischemic stroke (AIS). ? This is a major step forward in advancing stroke care, and allows U.S. and European patient enrollment to begin in 2025. Recent clinical trials have already demonstrated the promise of this technology, achieving significantly higher first-pass and frontline success rates compared to current benchmarks. ? At SANTé, we?are proud to work with companies such as Rapid?Pulse as they redefine treatment, and are optimistic for improved patient outcomes worldwide. https://lnkd.in/eMfccsR6?
关于我们
RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse? Aspiration System*, which includes a novel aspiration pump and catheters to allow rapid and consistent removal of blood clots from the brain. The RapidPulse logo and the word mark RapidPulseTM are trademarks of RapidPulse, Inc., and are the subject of applications pending in the United States and internationally. *The RapidPulseTM Aspiration System is not cleared for sale in the United States.
- 网站
-
https://rapidpulsemed.com/
RapidPulse, Inc.的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 11-50 人
- 类型
- 私人持股
RapidPulse, Inc.员工
-
Heather Harries
Collaborative Medical Device Chief Operating Officer Consistently Exceeding Business Targets
-
Maria Berkman, MD, MBA
MedTech VC Broadview Ventures | Longview Ventures
-
Jeff Terrell
General Partner at Hatteras Venture Partners, Medical Devices
-
Shanna Helminen
Senior Product Development Engineer